freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
Reconstitution concentration is chosen from the mass of peptide and the volume of solvent added. Researchers often prepare a concentrated stock and then divide it into single-use aliquots to reduce freeze-thaw cycling. The actual peptide content may differ from label mass because of counterions, water, or impurities. For that reason, quantitative work may require independent measurement such as amino acid analysis or ultraviolet absorbance. Records of solvent, volume, date, and lot help trace later observations.
Lyophilized peptides are supplied as dry powders or porous cakes that remain stable during shipment and short-term storage. Reconstitution is the laboratory step of adding a suitable solvent so the solid dissolves into a liquid stock. The dried state limits hydrolysis and microbial growth, but it does not remove all residual water or salts. Sequence, counterion, and manufacturing method influence how quickly and completely a peptide enters solution. Researchers treat reconstitution as a practical starting point for later dilution, analysis, or assay work.
Solvent choice depends on peptide polarity and intended use. Many peptides dissolve in water or buffered aqueous solutions, while hydrophobic sequences may need a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before aqueous dilution. The solvent should match the downstream analytical method and not interfere with detection. Gentle mixing or brief sonication can help, but vigorous agitation may promote foaming or aggregation. Complete dissolution is judged by a clear liquid free of visible particles, though some turbidity can persist.
Cloudiness, particles, or gel formation after reconstitution can signal incomplete dissolution, aggregation, or contamination. A clear solution is not proof of purity, and a cloudy one is not always unusable if the peptide is designed to form suspensions. pH measurement can identify whether the solution matches the intended range, and buffer exchange may be needed when the original solvent is incompatible. Sterile filtration is sometimes used for microbial control, but filters can adsorb peptides and reduce concentration. Documentation of lot number, solvent, volume, date, and storage condition supports later traceability in laboratory records.
Once a peptide is in liquid form, its stability depends on temperature, pH, concentration, and the presence of oxygen or microbes. Refrigeration slows many degradation pathways, while freezing can extend storage for longer periods. Repeated freeze-thaw cycles are generally avoided because ice crystal formation and concentration changes can promote aggregation. Light exposure can also damage peptides that contain aromatic or sulfur-containing residues. A common laboratory practice is to divide a reconstituted stock into single-use aliquots before freezing, but the optimal storage condition remains peptide-specific and is often determined empirically.
Analytical checks help determine whether a reconstituted peptide matches its expected identity and purity; reverse-phase high-performance liquid chromatography separates components by hydrophobicity and can reveal degradation products or impurities. Mass spectrometry provides a mass measurement that supports sequence identity when compared with the theoretical value. Ultraviolet absorbance at 280 nm can estimate concentration for peptides containing tryptophan or tyrosine, though sequence-dependent extinction coefficients are needed. For shorter or non-aromatic peptides, other methods such as amino acid analysis may be required. These techniques describe the material rather than guarantee its biological effect.
| Property | Value | Notes |
|---|---|---|
| Appearance (lyophilized) | White to off-white powder or cake | Depends on peptide sequence, counterion, and manufacturing process |
| Appearance (reconstituted) | Clear to slightly hazy solution | Visible particles may indicate incomplete dissolution or aggregation |
| Solubility class | Aqueous or organic-dependent | Hydrophilic peptides often dissolve in water; hydrophobic peptides may require acetonitrile or dimethyl sulfoxide |
| Typical storage temperature (lyophilized) | -20 °C or lower | Desiccated, protected from light, and allowed to equilibrate before opening |
| Typical analytical method | Reverse-phase HPLC or LC-MS | Used to confirm identity, purity, and concentration after dissolution |
During reconstitution, liquid is directed toward the wall of the vial rather than forcefully onto the powder. Gentle swirling or inversion mixes the contents without creating excessive foam or shear. Foaming can denature some peptides and can make volume measurement difficult. Complete dissolution is often confirmed by visual inspection against a light source. Particles, cloudiness, or undissolved material may indicate incomplete mixing, aggregation, or a solubility limitation that requires further investigation.
Peptide reconstitution is the addition of a liquid to a dried peptide preparation so that the peptide dissolves and forms a solution. Many research peptides are supplied as lyophilized powders, a form produced by freezing and then removing solvent under vacuum. The dried material often appears as a cake or fluffy powder. Dissolution depends on the peptide's sequence, charge, and hydrophobicity. Not all peptides dissolve equally in the same liquid.
The choice of solvent is guided by peptide properties and the intended downstream use. Water alone can dissolve many hydrophilic peptides, while hydrophobic sequences may require a small amount of an organic solvent or a buffered solution. Some peptides carry net charges that affect solubility across pH values. The pH of the final solution can influence stability and aggregation. In research settings, the solvent is selected to match the assay or analytical method rather than for any therapeutic purpose.
Solvent selection affects pH, ionic strength, and preservative content in the final liquid. Sterile water and bacteriostatic water containing benzyl alcohol are common in laboratory settings. Buffer systems may be used when a peptide is sensitive to pH shifts during dissolution. Acidic or basic conditions can change the net charge of ionizable groups and therefore solubility. Organic cosolvents are sometimes added for hydrophobic sequences, though they can also promote unfolding or aggregation.
During reconstitution, solvent penetrates the powder, breaks interparticle contacts, and solvates polar and nonpolar groups. Gentle mixing or swirling can speed dissolution, while vigorous shaking may introduce foaming and surface denaturation. Aggregation becomes more likely when the peptide concentration exceeds its solubility or when the pH is near the isoelectric point. The link between a specific reconstitution method and long-term stability is not fully predictable from sequence alone. How excipients, container surfaces, and residual moisture influence aggregation remains an open question.
Lyophilization removes water from a peptide solution under vacuum, leaving a porous cake or a loose powder. The dry form often improves stability during shipping and storage because water-mediated degradation slows. Reconstitution reverses the process by adding a solvent so peptide molecules hydrate and enter solution. Complete dissolution depends on peptide sequence, purity, salt form, and any excipients present. Some lyophilized powders dissolve quickly, while others form haze, gels, or persistent particles.
After reconstitution, peptide solutions are generally less stable than lyophilized powders, and hydrolysis, oxidation, deamidation, and aggregation can occur in solution. Stability depends on peptide sequence, concentration, pH, buffer composition, temperature, light exposure, and dissolved oxygen. Many research protocols store reconstituted solutions at 4 °C for short periods or at -20 °C or -80 °C for longer periods. Repeated freeze-thaw cycles can promote aggregation and loss of activity. The optimal storage condition is peptide-specific and often determined empirically rather than predicted from sequence alone.
Quality control after reconstitution often includes visual inspection for particulates, pH measurement, and concentration determination by ultraviolet absorbance at 280 nm when aromatic residues are present. Reverse-phase high-performance liquid chromatography can assess purity and reveal degradation peaks. Mass spectrometry confirms molecular identity and detects modifications such as oxidation or truncation. Size-exclusion chromatography can quantify aggregates and oligomers. These methods are established for many peptides but may require optimization for hydrophobic or chemically modified sequences.
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
The choice of solvent depends on the peptide's sequence, charge, and solubility profile. Water is common for hydrophilic peptides, while aqueous mixtures containing acetonitrile, methanol, or a small amount of acid may be needed for hydrophobic or basic sequences. Adding the liquid to the powder, rather than the reverse, can reduce clumping and improve wetting. Gentle mixing or brief vortexing may help, but vigorous agitation can create foam and shear sensitive structures. Complete dissolution is judged by a clear solution with no visible particles.
Buffer components and ionic strength affect how a peptide dissolves and remains in solution. Some sequences require a defined pH range to avoid precipitation or aggregation, while others tolerate pure water. The optimal conditions are often determined empirically because solubility cannot be predicted reliably from sequence alone. Even when a peptide dissolves, the resulting solution may contain aggregates that are not visible to the eye. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to confirm identity and purity after reconstitution.
== History == 2000: Four scientists from what was then the Agricultural University of Norway (NLH), now the Norwegian University of Life Sciences (UMB) had the idea of replacing traditional date-stamping with something that can give a more correct indication of remaining shelf life for temperature sensitive products, such as food and pharmaceuticals. 2001: The fundamental principles for a shelf-life indicator were verified in the laboratory. The company TimeTemp AS, now Keep-it Technologies, was founded in 2001 to develop the technology into a commercial product. 2003: TimeTemp comes in second place in DNB’s national innovation competition. 2003-2007: The technology is tested and developed in the university's laboratories, and a working laboratory prototype is created. Keep-it Technologies is granted a patent in a number of different countries, including the US, Canada, Australia and New Zealand. 2007-2009: With support from the Research Council of Norway, Keep-it Technologies initiates an R&D project to develop the technology from laboratory prototype to an industrial prototype, and test it on real products through a professional cold chain. 2010-2011: The company raises new investment capital and initiates an IFU project that develops the first consumer version of the indicator. The indicator is tested on the first products in the Norwegian grocery market. 2012: Keep-it indicator is commercialized in Norway with the Norwegian retailer, Rema 1000. 2018: Keep-it has indicators on 30 different fresh products at Rema 1000, Kolonial.no and Oslo University Hospital.
Lindow Moss is a peat bog in Lindow, an area of Wilmslow, Cheshire, which has been used as common land since the medieval period. It formed after the last ice age, one of many such peat bogs in north-east Cheshire and the Mersey basin that formed in hollows caused by melting ice. Investigations have not yet discovered settlement or agricultural activity around the edge of Lindow Moss that would have been contemporary with Lindow Man, but analysis of pollen in the peat suggests there was some cultivation in the vicinity. Once covering over 600 hectares (1,500 acres), the bog has now shrunk to a tenth of its original size. It is a dangerous place and an 18th-century writer recorded people drowning there. For centuries, the peat from the bog was used as fuel, and it continued to be extracted until the 1980s, by which time the process had been mechanised. Lindow Moss is a lowland raised mire, a type of peat bog which often produces the best-preserved bog bodies, allowing more detailed analysis. Lowland raised mires occur mainly in northern England and extend south to the Midlands. Lindow Man is one of 27 bodies to be recovered from such areas.
===== MeSH D08.811.277.656 – peptide hydrolases (EC 3.4) ===== MeSH D08.811.277.656.149 – atp-dependent proteases MeSH D08.811.277.656.149.200 – endopeptidase clp MeSH D08.811.277.656.149.500 – protease la MeSH D08.811.277.656.300 – endopeptidases MeSH D08.811.277.656.300.066 – aspartic endopeptidases MeSH D08.811.277.656.300.066.180 – cathepsin d MeSH D08.811.277.656.300.066.185 – cathepsin e MeSH D08.811.277.656.300.066.200 – chymosin MeSH D08.811.277.656.300.066.340 – HIV protease MeSH D08.811.277.656.300.066.700 – pepsin a MeSH D08.811.277.656.300.066.780 – renin MeSH D08.811.277.656.300.099 – brinolase MeSH D08.811.277.656.300.133 – cathepsins MeSH D08.811.277.656.300.133.062 – carboxypeptidase c MeSH D08.811.277.656.300.133.125 – cathepsin b MeSH D08.811.277.656.300.133.187 – cathepsin d MeSH D08.811.277.656.300.133.250 – cathepsin e MeSH D08.811.277.656.300.133.375 – dipeptidyl peptidase i MeSH D08.811.277.656.300.174 – coagulase MeSH D08.811.277.656.300.215 – cysteine endopeptidases MeSH D08.811.277.656.300.215.096 – bromelains MeSH D08.811.277.656.300.215.120 – calpain MeSH D08.811.277.656.300.215.126 – caspases MeSH D08.811.277.656.300.215.126.200 – caspase 1 MeSH D08.811.277.656.300.215.133 – cathepsin b MeSH D08.811.277.656.300.215.160 – chymopapain MeSH D08.811.277.656.300.215.350 – ficain MeSH D08.811.277.656.300.215.585 – papain MeSH D08.811.277.656.300.480 – metalloendopeptidases MeSH D08.811.277.656.300.480.205 – collagenases MeSH D08.811.277.656.300.480.205.352 – gelatinase a MeSH D08.811.277.656.300.480.205.360 – gelatinase b MeSH D08.811.277.656.300.480.205.410 – interstitial collagenase MeSH D08.811.277.656.300.480.205.500 – microbial collagenase MeSH D08.811.277.656.300.480.205.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.252 – gelatinases MeSH D08.811.277.656.300.480.252.420 – gelatinase a MeSH D08.811.277.656.300.480.252.445 – gelatinase b MeSH D08.811.277.656.300.480.300 – insulysin MeSH D08.811.277.656.300.480.452 – lysostaphin MeSH D08.811.277.656.300.480.525 – matrix metalloproteinases MeSH D08.811.277.656.300.480.525.352 – gelatinase a MeSH D08.811.277.656.300.480.525.360 – gelatinase b MeSH D08.811.277.656.300.480.525.451 – interstitial collagenase MeSH D08.811.277.656.300.480.525.505 – matrilysin MeSH D08.811.277.656.300.480.525.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.525.810 – stromelysin 1 MeSH D08.811.277.656.300.480.600 – neprilysin MeSH D08.811.277.656.300.480.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.300.480.664 – procollagen n-endopeptidase MeSH D08.811.277.656.300.480.680 – pronase MeSH D08.811.277.656.300.480.827 – thermolysin MeSH D08.811.277.656.300.760 – serine endopeptidases MeSH D08.811.277.656.300.760.030 – acrosin MeSH D08.811.277.656.300.760.176 – chymotrypsin MeSH D08.811.277.656.300.760.198 – complement factor b MeSH D08.811.277.656.300.760.200 – complement factor d MeSH D08.811.277.656.300.760.210 – complement factor i MeSH D08.811.277.656.300.760.228 – endopeptidase clp MeSH D08.811.277.656.300.760.247 – endopeptidase k MeSH D08.811.277.656.300.760.284 – enteropeptidase MeSH D08.811.277.656.300.760.300 – factor viia MeSH D08.811.277.656.300.760.310 – factor ixa MeSH D08.811.277.656.300.760.315 – factor xa MeSH D08.811.277.656.300.760.320 – factor xia MeSH D08.811.277.656.300.760.324 – factor xiia MeSH D08.811.277.656.300.760.353 – furin MeSH D08.811.277.656.300.760.442 – kallikreins MeSH D08.811.277.656.300.760.442.700 – plasma kallikrein MeSH D08.811.277.656.300.760.442.725 – prekallikrein MeSH D08.811.277.656.300.760.442.750 – prostate-specific antigen MeSH D08.811.277.656.300.760.442.875 – tissue kallikreins MeSH D08.811.277.656.300.760.501 – mannose-binding protein-associated serine proteases MeSH D08.811.277.656.300.760.560 – pancreatic elastase MeSH D08.811.277.656.300.760.560.500 – leukocyte elastase MeSH D08.811.277.656.300.760.625 – plasmin MeSH D08.811.277.656.300.760.635 – plasminogen activators MeSH D08.811.277.656.300.760.635.075 – anistreplase MeSH D08.811.277.656.300.760.640 – proprotein convertase 1 MeSH D08.811.277.656.300.760.646 – proprotein convertase 2 MeSH D08.811.277.656.300.760.648 – proprotein convertase 5 MeSH D08.811.277.656.300.760.680 – pronase MeSH D08.811.277.656.300.760.733 – protease la MeSH D08.811.277.656.300.760.787 – subtilisins MeSH D08.811.277.656.300.760.787.805 – subtilisin MeSH D08.811.277.656.300.760.855 – thrombin MeSH D08.811.277.656.300.760.875 – tissue plasminogen activator MeSH D08.811.277.656.300.760.895 – trypsin MeSH D08.811.277.656.300.760.910 – urinary plasminogen activator MeSH D08.811.277.656.300.760.955 – venombin a MeSH D08.811.277.656.300.760.955.060 – ancrod MeSH D08.811.277.656.300.760.955.135 – batroxobin MeSH D08.811.277.656.300.775 – streptokinase MeSH D08.811.277.656.300.775.075 – anistreplase MeSH D08.811.277.656.300.775.900 – streptodornase and streptokinase MeSH D08.811.277.656.350 – exopeptidases MeSH D08.811.277.656.350.100 – aminopeptidases MeSH D08.811.277.656.350.100.150 – amino acid naphthylamidases MeSH D08.811.277.656.350.100.150.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.160 – antigens, cd13 MeSH D08.811.277.656.350.100.235 – cystinyl aminopeptidase MeSH D08.811.277.656.350.100.373 – glutamyl aminopeptidase MeSH D08.811.277.656.350.100.511 – leucyl aminopeptidase MeSH D08.811.277.656.350.100.511.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.755 – pyroglutamyl-peptidase I MeSH D08.811.277.656.350.245 – carboxypeptidases MeSH D08.811.277.656.350.245.055 – carboxypeptidases A MeSH D08.811.277.656.350.245.083 – carboxypeptidase B MeSH D08.811.277.656.350.245.111 – carboxypeptidase C MeSH D08.811.277.656.350.245.167 – carboxypeptidase H MeSH D08.811.277.656.350.245.224 – carboxypeptidase U MeSH D08.811.277.656.350.245.252 – Serine-type D-Ala-D-Ala carboxypeptidase MeSH D08.811.277.656.350.245.280 – gamma-glutamyl hydrolase MeSH D08.811.277.656.350.245.400 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.245.450 – lysine carboxypeptidase MeSH D08.811.277.656.350.245.500 – muramoylpentapeptide carboxypeptidase MeSH D08.811.277.656.350.297 – dipeptidases MeSH D08.811.277.656.350.350 – dipeptidyl peptidases MeSH D08.811.277.656.350.350.126 – antigens, cd26 MeSH D08.811.277.656.350.350.375 – dipeptidyl peptidase i MeSH D08.811.277.656.350.555 – metalloexopeptidases MeSH D08.811.277.656.350.555.100 – antigens, cd13 MeSH D08.811.277.656.350.555.200 – carboxypeptidase b MeSH D08.811.277.656.350.555.250 – carboxypeptidase h MeSH D08.811.277.656.350.555.300 – carboxypeptidase u MeSH D08.811.277.656.350.555.350 – carboxypeptidases a MeSH D08.811.277.656.350.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.350.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.350.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.350.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.350.700 – peptidyl-dipeptidase a MeSH D08.811.277.656.675 – metalloproteases MeSH D08.811.277.656.675.374 – metalloendopeptidases MeSH D08.811.277.656.675.374.102 – adam proteins MeSH D08.811.277.656.675.374.205 – collagenases MeSH D08.811.277.656.675.374.205.352 – gelatinase a MeSH D08.811.277.656.675.374.205.360 – gelatinase b MeSH D08.811.277.656.675.374.205.410 – interstitial collagenase MeSH D08.811.277.656.675.374.205.500 – microbial collagenase MeSH D08.811.277.656.675.374.205.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.252 – gelatinases MeSH D08.811.277.656.675.374.252.420 – gelatinase a MeSH D08.811.277.656.675.374.252.445 – gelatinase b MeSH D08.811.277.656.675.374.300 – insulysin MeSH D08.811.277.656.675.374.452 – lysostaphin MeSH D08.811.277.656.675.374.525 – matrix metalloproteinases MeSH D08.811.277.656.675.374.525.352 – gelatinase a MeSH D08.811.277.656.675.374.525.360 – gelatinase b MeSH D08.811.277.656.675.374.525.451 – interstitial collagenase MeSH D08.811.277.656.675.374.525.505 – matrilysin MeSH D08.811.277.656.675.374.525.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.525.810 – stromelysin 1 MeSH D08.811.277.656.675.374.600 – neprilysin MeSH D08.811.277.656.675.374.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.675.374.664 – procollagen n-endopeptidase MeSH D08.811.277.656.675.374.680 – pronase MeSH D08.811.277.656.675.374.827 – thermolysin MeSH D08.811.277.656.675.555 – metalloexopeptidases MeSH D08.811.277.656.675.555.100 – antigens, cd13 MeSH D08.811.277.656.675.555.200 – carboxypeptidase b MeSH D08.811.277.656.675.555.250 – carboxypeptidase h MeSH D08.811.277.656.675.555.300 – carboxypeptidase u MeSH D08.811.277.656.675.555.350 – carboxypeptidases a MeSH D08.811.277.656.675.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.675.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.675.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.675.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.675.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.675.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.837 – proprotein convertases MeSH D08.811.277.656.837.124 – carboxypeptidase h MeSH D08.811.277.656.837.186 – carboxypeptidase u MeSH D08.811.277.656.837.249 – furin MeSH D08.811.277.656.837.500 – proprotein convertase 1 MeSH D08.811.277.656.837.562 – proprotein convertase 2 MeSH D08.811.277.656.837.625 – proprotein convertase 5 MeSH D08.811.277.656.837.750 – renin MeSH D08.811.277.656.918 – proteasome endopeptidase complex
The analyte molecules in a sample can be partially ordered with respect to the external magnetic field of the spectrometer by manipulating the sample conditions. Common techniques include addition of bacteriophages or bicelles to the sample, or preparation of the sample in a stretched polyacrylamide gel. This creates a local environment that favours certain orientations of nonspherical molecules. Normally in solution NMR the dipolar couplings between nuclei are averaged out because of the fast tumbling of the molecule. The slight overpopulation of one orientation means that a residual dipolar coupling remains to be observed. The dipolar coupling is commonly used in solid state NMR and provides information about the relative orientation of the bond vectors relative to a single global reference frame. Typically the orientation of the N-H vector is probed in an HSQC-like experiment. Initially, residual dipolar couplings were used for refinement of previously determined structures, but attempts at de novo structure determination have also been made.
The progressive miniaturization of low-voltage lighting technology, such as LEDs and OLEDs, suitable to incorporate into low-thickness materials has fostered experimentation in combining light sources and wall covering surfaces for interior walls in the form of LED wallpaper.
Sources: en.wikipedia.org
== Structure == Although no crystallographic x-ray diffraction analyses have been published that depict the entire structure of ADAM10, one domain has been studied using this technique. The disintegrin and cysteine-rich domain (shown to the right) plays an essential role in regulation of protease activity in vivo. Recent experimental evidence suggests that this region, which is distinct from the active site, may be responsible for substrate specificity of the enzyme. It is proposed that this domain binds to particular regions of the enzyme's substrate, allowing peptide bond hydrolysis to occur in well defined locations on certain substrate proteins. The proposed active site of ADAM10 has been identified by sequence analysis, and is identical to enzymes in the Snake Venom metalloprotein domain family. The consensus sequence for catalytically active ADAM proteins is HEXGHNLGXXHD. Structural analysis of ADAM17, which has the same active site sequence as ADAM10, suggests that the three histidines in this sequence bind a Zn2+ atom, and that the glutamate is the catalytic residue.
To do this, known controls are tested consecutively with unknown samples. By comparing the readouts of the controls with their known profiles the instrument can be confirmed to have been working properly at the time the unknowns were tested. Standards are also used to determine the instrument's limit of detection and limit of quantification for various common substances. Calculated quantities must be above the limit of detection to be confirmed as present and above the limit of quantification to be quantified. If the value is below the limit the value is not considered reliable.
The Christian New Testament notes that some people thought that Jesus was, in some sense, Elijah, but it also makes clear that John the Baptist is "the Elijah" who was promised to come in Malachi 3:1; 4:5. According to accounts in all three of the Synoptic Gospels, Elijah appeared with Moses during the Transfiguration of Jesus. In Western Christianity, Elijah is commemorated as a saint with a feast day on 20 July by the Roman Catholic Church and the Lutheran Church–Missouri Synod. Catholics believe that he was unmarried and celibate. In the Eastern Orthodox Church and those Eastern Catholic Churches which follow the Byzantine Rite, he is commemorated on the same date (in the 21st century, Julian Calendar 20 July corresponds to Gregorian Calendar 2 August). He is greatly revered among the Orthodox as a model of the contemplative life. He is also commemorated on the Orthodox liturgical calendar on the Sunday of the Holy Fathers (the Sunday before the Nativity of the Lord). John the Baptist is also known as John the Forerunner in Christianity, John the Immerser in some Baptist Christian traditions, He is considered to be a prophet of God by all of these faiths, and is honoured as a saint in many Christian denominations. According to the New Testament, John anticipated a messianic figure greater than himself, and the Gospels portray John as the precursor or forerunner of Jesus, since John announces Jesus' coming and prepares the people for Jesus' ministry.
=== Women's health === Sexual intercourse between women and circumcised, as compared to uncircumcised, men is associated with a decreased risk of cervical cancer, cervical dysplasia, HSV-2, chlamydia, and syphilis among women. The evidence is less consistent in regard to an association of circumcision with women's risk of HPV and HIV.
==== Saline implants ==== The saline breast implant—filled with saline solution (biological-concentration salt water 0.90% w/v of NaCl, ca. 300 mOsm/L.)—was first manufactured by the Laboratoires Arion company, in France, and was introduced for use as a prosthetic medical device in 1964. The contemporary models of saline breast implant are manufactured with thicker, room-temperature vulcanized (RTV) shells made of a silicone elastomer. The study In vitro Deflation of Pre-filled Saline Breast Implants (2006) reported that the rates of deflation (filler leakage) of the pre-filled saline breast implant made it a second-choice prosthesis for corrective breast surgery. Nonetheless, in the 1990s, the saline breast implant was the prosthesis most common device used for breast augmentation surgery in the United States, because of the U.S. FDA's restriction against the implantation of silicone-filled breast implants outside of clinical studies. Saline breast implants have enjoyed little popularity in the rest of the world, possessing negligible market share. The technical goal of saline-implant technology was a physically less invasive surgical technique for emplacing an empty breast implant device through a smaller surgical incision.
Sources: en.wikipedia.org
The solvent depends on peptide sequence and application. Water or aqueous buffer works for many hydrophilic peptides, while hydrophobic peptides may require a water-miscible organic solvent. The chosen solvent must be compatible with the assay or analytical instrument.
No. Some material may remain as insoluble particles, adsorb to surfaces, or degrade during handling. Recovery can be checked by analytical methods such as chromatography or mass spectrometry.
Aliquoting limits repeated freezing and thawing, which can cause aggregation or loss. Single-use portions also reduce contamination risk. Storage conditions depend on peptide stability.
Short-term storage is often under refrigeration, while longer storage may use freezing at -20 °C or lower. The choice depends on peptide stability and the solvent. Dividing the solution into aliquots reduces repeated temperature changes.